Sarepta Therapeutics
SRPT
128 hedge funds and large institutions have $794M invested in Sarepta Therapeutics in 2014 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 45 increasing their positions, 41 reducing their positions, and 13 closing their positions.
108% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 13
24% more capital invested
Capital invested by funds: $639M → $794M (+$156M)
12% more funds holding
Funds holding: 114 → 128 (+14)
10% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 41
22% less call options, than puts
Call options by funds: $51.2M | Put options by funds: $65.6M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$21.3M |
| 2 |
SFM
Soros Fund Management
New York
|
+$20.7M |
| 3 |
PC
PointState Capital
New York
|
+$6.32M |
| 4 |
Millennium Management
New York
|
+$6.21M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$12.2M |
| 2 |
PA
Perceptive Advisors
New York
|
-$10.1M |
| 3 |
JG
Jefferies Group
New York
|
-$8.55M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$7.12M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$6.57M |
SRPT Hedge Fund Activity: Q2 2014 in Review
128 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q2 2014, worth a combined $794M — up 24% from $639M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new SRPT positions and 13 closed out — a net gain of 14 holders — while 45 added to existing stakes and 41 trimmed.
The largest buyer was D.E. Shaw & Co, adding an estimated $21.3M. The largest seller was Susquehanna International Group, cutting an estimated $12.2M.
- 128 institutional investors held Sarepta Therapeutics (SRPT) as of Q2 2014, up from 114 in Q1 2014.
- Funds reported $794M of Sarepta Therapeutics stock for Q2 2014, up 24% quarter-over-quarter.
- 27 funds opened new Sarepta Therapeutics positions in Q2 2014 and 13 closed out, a net change of +14 holders.
- The largest Sarepta Therapeutics buyer in Q2 2014 was D.E. Shaw & Co, an estimated $21.3M added.
- The largest Sarepta Therapeutics seller in Q2 2014 was Susquehanna International Group, an estimated $12.2M sold.
Based on aggregated 13F filings for Q2 2014.